Evaluation of RSB11-HI Postbiotic Supplementation for Supporting Weight Management, Metabolic Wellness, and Quality of Life in Healthy Adults

Part of paid clinical trials in Dallas, Texas.

Sponsor
Able Biolabs, LLC
Study ID
NCT07788833
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Adults

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • RSB11-HI Heat-Inactivated Postbiotic — DIETARY_SUPPLEMENT
    RSB11-HI is a heat-inactivated postbiotic derived from Lactiplantibacillus plantarum RSB11. Participants will receive the assigned study product orally once daily for 8 consecutive weeks according to the study dosing instructions.
  • Placebo — OTHER
    Matched placebo administered orally once daily for 8 consecutive weeks. The placebo is identical in appearance, packaging, labeling, and administration schedule to the RSB11-HI study product to maintain blinding.

Study Details

This randomized, double-blind, placebo-controlled clinical trial will evaluate the safety, tolerability, and efficacy of RSB11-HI, a heat-inactivated postbiotic, in healthy adults over an 8-week intervention period. Participants will be classified into one of three predefined study populations-General Healthy, Perimenopausal, or Mild Inflammation-and will then be randomized within their assigned population to receive either RSB11-HI or placebo. The study will evaluate the effects of supplementation on healthy weight management, metabolic wellness, gastrointestinal health, and quality of life, while also exploring whether responses differ among the predefined study populations.

Key Dates

First listed
Aug 27, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: RSB11-HI Heat-Inactivated Postbiotic
    Participants assigned to this arm will receive RSB11-HI Heat-Inactivated Postbiotic orally once daily for 8 consecutive weeks according to the study dosing instructions.
  • Placebo Comparator: Placebo
    Participants assigned to this arm will receive the matched placebo orally once daily for 8 consecutive weeks according to the study dosing instructions. The placebo is identical in appearance, packaging, labeling, and administration schedule to the RSB11-HI study product to maintain blinding.

Primary Outcome Measure

Change in Body Weight From Baseline to Week 8 [ Time Frame: Baseline to Week 8 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Able Biolabs LLCDallasTexas75247
Clinical Trials Coordinator
[email protected]
617-634-3675

Find similar trials in Dallas, TX

By research site
Able Biolabs LLC· Dallas, TX

Related Studies